Article

Status of diabetes care among community pharmacy patients with diabetes: Analysis of the Medical Expenditure Panel Survey

College of Pharmacy, University of Tennessee, Memphis, TN 38163, USA.
Journal of the American Pharmacists Association (Impact Factor: 1.24). 07/2010; 50(4):478-84. DOI: 10.1331/JAPhA.2010.08173
Source: PubMed

ABSTRACT

To determine the status of diabetes care among community pharmacy patients with diabetes.
Cross-sectional observational study.
United States, 2005.
1,455 community pharmacy patients aged 18 years or older with diabetes who were diagnosed before 2005.Intervention: Analysis of the Medical Expenditure Panel Survey.
Proportions of patients meeting American Diabetes Association (ADA) standards of medical care in diabetes.
In 2005, 1,455 patients with diabetes who were diagnosed before 2005 filled prescriptions through community pharmacies. Gaps occurred between the diabetes care of these patients and ADA standards. Examples include the following: ADA recommends at least two glycosylated hemoglobin (A1C) tests annually, but 19.52% of the study population reported less than two A1C tests in 2005; ADA recommends annual influenza vaccinations, but 42.46% of the study population reported not receiving an influenza vaccination in 2005; and ADA recommends weight control, but 83.74% of the study population was overweight or obese.
The current results demonstrate that many patients with diabetes are not receiving adequate care and that pharmacists have an opportunity to improve diabetes management.

0 Followers
 · 
7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Medicare Modernization Act of 2003 requires prescription drug plans to provide medication therapy management (MTM) services to Medicare beneficiaries who are at high risk for inappropriate use of medications. However, inadequate compensation has been a barrier for MTM expansion among pharmacists. The objective of this study was to determine pharmacists' acceptable levels of compensation for MTM services. A preference-based fractional factorial design of conjoint analysis was used by surveying 1524 active pharmacists in Tennessee. Pharmacists were asked to select between packages (scenarios) of MTM services that represented combinations of MTM attributes (characteristics). The MTM attributes included type of patient (new or returning), patient's number of chronic conditions (1, 3, or 6), patient's number of medications (4, 8, or 16), patient's annual drug costs ($2000, $3000, or $4000), service duration (15 minutes, 30 minutes, or 45 minutes), and price of MTM services ($30, $60, or $120). A survival analysis model was used to predict pharmacists' willingness to select 1 versus another MTM service package. Pharmacists' acceptable level of compensation was estimated as the marginal rate of substitution between the parameter estimates of an attribute and the price attribute of MTM. The parameter estimates were -0.0303 (P<.0001) for service duration and 0.0210 (P<.0001) for price of MTM services, respectively, so pharmacists were willing to accept $1.44/min (0.0303/0.0210), or $86.4/h, for MTM services. Pharmacists' characteristics were associated significantly with their acceptable levels of compensation: years of practice was associated with a higher need for compensation, pharmacy ownership (vs nonowner) associated with a lower need, and having provided MTM previously (vs having not provided MTM) was associated with a higher need. Pharmacists' acceptable level of compensation is in the higher part of current ranges from $30 to $100/h. To increase participation in MTM services, pharmacist compensation needs to be increased. Future studies might continue to corroborate the generalizability of findings from this study.
    No preview · Article · Nov 2010 · Research in Social and Administrative Pharmacy
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the costs related to visits and drug prescription in outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. A prospective and experimental study was carried out. Seventy one patients were divided into two groups: control and pharmaceutical care. Patients in the pharmaceutical care group were followed up monthly by a single clinical pharmacist. The pharmaceutical care group had a statistically significant reduction in costs of metformin and emergency department visits, and increased costs with their family physicians. On the other hand, the control group had a statistically significant increase of 21.3% in the general costs of treatment and visits. The pharmaceutical care group maintained the same costs related to drugs and visits, while the control group showed a significant increase in general costs.
    Full-text · Article · Dec 2011 · Arquivos brasileiros de endocrinologia e metabologia